Cargando…
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
BACKGROUND: In the randomized phase 3 GALLIUM trial, first-line treatment with obinutuzumab (GA101; G) plus chemotherapy (G + chemo) resulted in superior progression-free survival (PFS) compared with rituximab plus chemotherapy (R + chemo) for patients with follicular lymphoma (FL). G + chemo was fo...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394221/ https://www.ncbi.nlm.nih.gov/pubmed/33586513 http://dx.doi.org/10.18553/jmcp.2021.20424 |